2. Mission
Future Diagnostics intends to become the best developer for
third parties of high‐quality and innovative diagnostic tests,
today, and in the future, seen in the eyes of our customers and
our employees.

3. Vision
Future Diagnostics intends to become the market leader in test
development for third parties
We want to become the independent partner of the top 25 IVD
companies for their test development
We would like to achieve this position by translating new
technologies and novel ‘Intellectual Properties’ to the
development of innovative tests with the shortest possible
development time at the lowest possible costs

4. Facts
Founded May 01st, 1997
Privately owned
Current number of employees is 65
Current number of projects is 35 out of a maximum of 40
Highly qualified staff
ISO 9001/2000 and ISO 13485 compliant
FDA inspections in 2004 and 2008

5. Objective
The development of diagnostic tests and technologies for
third parties
We are able to carry out development projects on almost any
platform
Antibody Screening
Feasibility
Optimization
Verification
Technical Validation
Clinical Validation
Pilot Production
Support in 510(k) filing and CE registration

7. Facilities
Total 3500 m2
( Lab: 2000 m2 )
Operational February 2011

9. > 120 developed assays
Bone Fertility Cancer
Bioactive PTH Aldosterone β‐2M
Calcitonin Androstendione EGF
Cip and Cap 11‐Desoxy‐cortisol EGF receptor
DPD DHEA E2 receptor
Intact‐PTH DHEA‐S Free PSA
PTH DHT IGF‐1
PTHrp Estradiol IGFBP3
1,25‐OH Vitamin D Estriol P53
25‐OH Vitamin D Free testosterone Progesterone receptor
Vitamin D BP hCG PSA
LH
17‐OH Progesterone
SHBG
Testosterone

10. Cardiovascular Endocrine Infectious disease
Angiotensin ACTH Anti‐HBc
ANP Anti‐Tg Anti‐HBs
BNP Anti‐TPO CMV IgG+IgM
Catecholamines C‐peptide EBV
CK‐MB Corticosteron Gonorrhea
D‐Dimer Cortisol HBcT
Factor VIII Cortison HBsAg
Fibrin‐monomer HbA1c HBsAg confirmative
Fibrinogen Fecal Occult Blood HCV
Galectin‐3 Free T3 HIV Ab
HS‐CRP Gastrin HIV Ag+Ab
Myoglobin GHBP HIV‐1,2,”O”
NT Pro‐BNP hGH Lyme
Protein‐C IL‐2 receptor Rubella IgG+IgM
Pro‐renin IL‐6 Syphilis
Renin Insulin Toxoplasmosis IgG+IgM
cTroponin Melatonin Tuberculosis
t‐PA‐PAI‐1 Newborn screening
uPA‐PAI‐1 Thyroglobulin
Vasopressin
vWF

11. IntraOperative Autoimmune
STAT‐ACTH Anti‐Cardiolipin IgG+ IgM
STAT‐C‐peptide Anti‐GAD
STAT‐Insulin Anti‐IA2
STAT‐Intact PTH Anti‐Insulin
Anti‐SMS
Multiplex auto antibodies
Anemia Drugs of Abuse Others
EPO Atrazine cGMP
Ferritin DES CGRP
Folate Salbutamol Cow Milk Progesterone
Vitamin B12 FPA
MAP2
Opsin
Rhodopsin
S100
Tyrosine Kinase

12. Our Customers

13. Experience on many platforms
Immuno analyzers
Chemistry analyzers
Other

14. Partnerships
Intellectual Property Vitamin D
Intellectual Property HbA1c

15. Experience in Technologies
Chemiluminescence
Bioluminescence
Fluorescence
Enzyme Based Immuno Assay
Colorimetric Assays
Turbidimetric Assays
DNA Assays
Point of Care

16. How we make our lab yours?
Balanced out = Shared Risk
Monthly Fee Royalties on sales

18. Wie is mijn klant?

19. Wie is mijn klant?
R&D of Business Development

20. Wat voor businessmodel?
Fee of een royalty project?

21. Wat voor businessmodel?
Fee of een royalty project?
Wat is bepalend voor deze keus??

22. Hoe controleer ik mijn royalty
inkomsten?

23. Hoe controleer ik mijn royalty
inkomsten?
Hoe is FDx er zeker van dat het
minimaal haar gemaakte kosten
terugverdiend?

24. Personeel
Hoe vang ik mijn piekbelasting op?

25. Liquiditeit
Hoe blijf ik aan mijn kortlopende
verplichtingen voldoen?

27. Trends in healthcare
• Less than 5% of the $3 trillion spent each year on the
health care worldwide is for clinical laboratory services.
• Considering that nearly 70% of health care decisions
are based on critical diagnostics information,
biomedical testing represents a significant source of
value in healthcare.
Source: TriMark Publications

28. 28 7/21/2011

29. Thank you for your attention